Document Detail


Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
MedLine Citation:
PMID:  19617666     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Dialysis-induced oxidative stress is one of the mechanisms of atherosclerotic changes. Heparin, used in hemodialysis, is an anticoagulant drug with anti-inflammatory and antioxidant effects. This study was planned in order to evaluate the antioxidant effects of heparin and dalteparin (low-molecular weight heparin). MATERIALS AND METHODS: Twenty-two patients underwent 3 hemodialysis sessions with 48-hour intervals. They underwent hemodialysis with heparin, with a bolus dose of 1000 U followed by 1000 U/h during the procedure. The second hemodialysis was done using hypertonic saline solution instead of heparin, and the third, using dalteparin, 4000 U, infused during hemodialysis. Before and after each dialysis session, we measured serum levels of total blood cholesterol, triglyceride, high- and low-density lipoprotein cholesterols and oxidized low-density lipoprotein cholesterol, in addition to total antioxidant capacity and paraoxonase 1 activity. RESULTS: Serum concentrations of triglyceride, cholesterol, and oxidized low-density lipoprotein cholesterol, as well as paraoxonase activity and total antioxidant capacity equally increased after the three hemodialysis sessions. Heparin and daltepain increased total antioxidant capacity, but they did not change the ratio of paraoxonase 1 to high-density lipoprotein cholesterol after hemodialysis. No significant differences were found through the study between the two heparin products in their antioxidant activities. CONCLUSIONS: Regarding these findings and considering higher price and less availability of dalteparin in comparison to conventional heparin, we recommend using conventional heparin during hemodialysis as the anticoagulant-antioxidant agent.
Authors:
Amir Ahmad Nassiri; Monir Sadat Hakemi; Mehrdad Soulati; Mehran Marashian; Khosrow Rahbar; Fereidoun Azizi
Related Documents :
8440546 - Effect of running exercise on proteoglycans and collagen content in the intervertebral ...
22062816 - Prediction of the chemical composition of freeze dried ostrich meat with near infrared ...
3052976 - Heparinized materials for control of the formation of the laminectomy membrane in exper...
22522416 - The impact of commercial rodent diets on the induction of tumours and flat aberrant cry...
2500576 - Increased urinary prostaglandin excretion in galactose-fed rats.
109556 - Effects of continuous and intermittent feeding on biliary lipid outputs in man: applica...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Iranian journal of kidney diseases     Volume:  3     ISSN:  1735-8582     ISO Abbreviation:  Iran J Kidney Dis     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-20     Completed Date:  2009-10-16     Revised Date:  2010-02-22    
Medline Journal Info:
Nlm Unique ID:  101316967     Medline TA:  Iran J Kidney Dis     Country:  Iran    
Other Details:
Languages:  eng     Pagination:  162-7     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran. nassiri@ams.ac.ir
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anticoagulants / administration & dosage*,  economics
Aryldialkylphosphatase / blood
Dalteparin / administration & dosage*,  economics
Drug Costs
Female
Heparin / administration & dosage*,  economics
Humans
Kidney Failure, Chronic / economics,  therapy*
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Male
Middle Aged
Oxidative Stress / drug effects*
Renal Dialysis*
Thrombosis / economics,  prevention & control
Triglycerides / blood
Young Adult
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Dalteparin; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Triglycerides; 0/oxidized low density lipoprotein; 9005-49-6/Heparin; EC 3.1.8.1/Aryldialkylphosphatase; EC 3.1.8.1/PON1 protein, human
Comments/Corrections
Erratum In:
Iran J Kidney Dis. 2009 Oct;3(4):255

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Marital adjustment in patients on long-term hemodialysis: a case-control study.
Next Document:  Giant angiomyolipoma associated with a dilated vessel prone to hemorrhage.